- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
RadNet buys nine centers, sells one
FDA clears Ziehm mobile C-arm
RadNet buys nine centers, sells one
No sooner had RadNet completed its two-month-old deal to acquire nine New Jersey imaging centers than the company began whittling down the purchase price, turning new assets into hard cash. RadNet sold off a single-modality open MRI center in southern New Jersey, along with some legacy image management systems, for $650,000, thus retrieving a chunk of the $2.1 million paid to Medical Resources for the nine facilities. Tristate Imaging bought the center, which RadNet described as being outside the market served by the closest RadNet centers. The acquisition price will drop further if RadNet sells, as planned, a building in Union, NJ, that it acquired in the deal. The Medical Resources acquisition is part of a strategy to connect RadNet's Mid-Atlantic and southern New York operations. These complement core operations in California, Maryland, and Delaware. All told, RadNet operates a network of 175 fully owned and operated outpatient imaging centers.
FDA clears Ziehm mobile C-arm
The FDA has cleared the Vision RFD, a mobile C-arm from Ziehm Imaging. The compact system is designed for use in endovascular surgery, interventional cardiology, and interventional radiology. It features a flat-panel sensor as part of its digital imaging chain. A large C-arm opening and 165º orbital rotation allow easy patient access.
CT Study Reveals Key Indicators for Angiolymphatic Invasion in Non-Small Cell Lung Cancer
January 15th 2025In computed tomography (CT) scans for patients with solid non-small cell lung cancer (NSCLC) < 30 mm, emerging research suggests the lollipop sign is associated with a greater than fourfold likelihood of angiolymphatic invasion.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
Shaping the Future of Radiology in 2025: Trends, Threats, and Opportunities
January 10th 2025How do we respond to challenges with staff recruitment, cybersecurity, and looming hospital takeovers in radiology? This author assesses key trends in radiology and offers key insights to stay competitive in the field.
